←
Penn Medicine Cancer5,679 posts
Penn Medicine Cancer avatar✓

Penn Medicine Cancer ✓

@PennCancer

Penn Medicine Cancer is dedicated to delivering innovative and compassionate care and providing the latest research advancements in cancer.

◷ Joined May 2013▧ 1,502 Photos and videos
Penn Medicine Cancer avatar
Penn Medicine Cancer@PennCancer·Nov 9

Penn Medicine has launched the Troiano Brain Tumor Center, a new initiative focused on developing innovative Tx for malignant brain tumors, including immunotherapies & RNA-based approaches designed to overcome tumors’ ability to evade the immune system. spr.ly/6014BHQADE

Fox Chase Cancer Center avatar
⟳ Penn Medicine Cancer retweeted
Fox Chase Cancer Center@FoxChaseCancer·Nov 8

Thank you to everyone who attended the 2026 Philadelphia Lung Cancer Symposium and special thanks to program directors Hossein Borghaei, DO, MS, of Fox Chase and Charu Aggarwal, MD, MPH, of @PennCancer for leading a day of learning in lung cancer care: bit.ly/4gN1ycW

Post attachmentPost attachmentPost attachmentPost attachment
AACR Foundation avatar
⟳ Penn Medicine Cancer retweeted
AACR Foundation@AACRFoundation·Oct 22

"[Research] is the beating heart of progress." Party with a Purpose Scientific Achievement Award Honoree and AACR President-Elect, Dr. Robert Vonderheide, explains that research is key to understanding the biology of cancer and developing new treatments for patients. @PennCancer

1:17
Penn Medicine Cancer avatar
Penn Medicine Cancer@PennCancer·Oct 22

Carmen Guerra, MD, led a study that found AI has the potential to translate clinical trial documents into another language with high accuracy. “We’re a lot closer than we thought to having these models assist us in translating." @GoHealio spr.ly/6013BH8NRT

Penn Cancer Innovation avatar
⟳ Penn Medicine Cancer retweeted
Penn Cancer Innovation@PC3Innovation·Oct 20

Join PC3I and @PennCancer tomorrow at 12pm for our 3rd annual Justin Bekelman Lectureship in Cancer Care Innovation, featuring @ASCO President-elect, Dr. Deb Schrag! This event is free with a complimentary lunch to follow.

Post attachment
Penn Medicine Cancer avatar
Penn Medicine Cancer@PennCancer·Oct 20

In a nationwide study of more than 12,000 patients with blood cancers, insurers initially rejected most prescriptions for specialty oral anticancer medications. The study was led by Penn's Jalpa Doshi, PhD. spr.ly/6018BH82Q6

Penn Medicine Cancer avatar
Penn Medicine Cancer@PennCancer·Oct 15

A phase-2 trial is testing whether a one-time injection of JNJ-1900 (NBTXR3) can improve outcomes in unresectable stage III NSCLC when added to standard chemoradiation & immunotherapy. David DiBardino, MD, is an investigator on the trial. @cure_today spr.ly/6015BGLsg7